Resultados da busca - Rupkatha Mukhopadhyay

  • Mostrando 1 - 9 resultados de 9
Refinar Resultados
  1. 1
    Restoration of IFNγR Subunit Assembly, IFNγ Signaling and Parasite Clearance in Leishmania donovani Infected Macrophages: Role of Membrane Cholesterol

    Restoration of IFNγR Subunit Assembly, IFNγ Signaling and Parasite Clearance in Leishmania donovani Infected Macrophages: Role of Membrane Cholesterol por Subha Sen, Koushik Roy, Sandip Mukherjee, Rupkatha Mukhopadhyay, Syamal Roy

    Publicado em 2011
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  2. 2
    Imipramine Is an Orally Active Drug against Both Antimony Sensitive and Resistant Leishmania donovani Clinical Isolates in Experimental Infection

    Imipramine Is an Orally Active Drug against Both Antimony Sensitive and Resistant Leishmania donovani Clinical Isolates in Experimental Infection por Sandip Mukherjee, Budhaditya Mukherjee, Rupkatha Mukhopadhyay, Kshudiram Naskar, Shyam Sundar, Jean‐Claude Dujardin, Anjan Kumar Das, Syamal Roy

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  3. 3
    The lignan niranthin poisons <i>Leishmania donovani</i> topoisomerase IB and favours a Th1 immune response in mice

    The lignan niranthin poisons <i>Leishmania donovani</i> topoisomerase IB and favours a Th1 immune response in mice por Sayan Mullick Chowdhury, Tulika Mukherjee, Rupkatha Mukhopadhyay, Budhaditya Mukherjee, Souvik Sengupta, Sharmila Chattopadhyay, Parasuraman Jaisankar, Syamal Roy, Hemanta K. Majumder

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  4. 4
    Role of nucleotide-binding oligomerization domain 1 (NOD1) and its variants in human cytomegalovirus control in vitro and in vivo

    Role of nucleotide-binding oligomerization domain 1 (NOD1) and its variants in human cytomegalovirus control in vitro and in vivo por Yi-Hsin Fan, Sujayita Roy, Rupkatha Mukhopadhyay, Arun Kapoor, Priya Duggal, Genevieve L. Wojcik, Robert F. Pass, Ravit Arav‐Boger

    Publicado em 2016
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  5. 5
    Antimony-resistant but not antimony-sensitive<i>Leishmania donovani</i>up-regulates host IL-10 to overexpress multidrug-resistant protein 1

    Antimony-resistant but not antimony-sensitive<i>Leishmania donovani</i>up-regulates host IL-10 to overexpress multidrug-resistant protein 1 por Budhaditya Mukherjee, Rupkatha Mukhopadhyay, Bijoylaxmi Bannerjee, Sayan Mullick Chowdhury, Sandip Mukherjee, Kshudiram Naskar, Uday Sankar Allam, Dipshikha Chakravortty, Shyam Sundar, Jean‐Claude Dujardin, Syamal Roy

    Publicado em 2013
    Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  6. 6
    Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy

    Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy por Hanna A. Knaus, Sofia Berglund, Hubert Hackl, Amanda L. Blackford, Joshua F. Zeidner, Raul Montiel‐Esparza, Rupkatha Mukhopadhyay, Katrina Vanura, Bruce R. Blazar, Judith E. Karp, Leo Luznik, Ivana Gojo

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  7. 7
    Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus

    Efficacy and Mechanism of Action of Low Dose Emetine against Human Cytomegalovirus por Rupkatha Mukhopadhyay, Sujayita Roy, Rajkumar Venkatadri, Yu‐Ping Su, Wenjuan Ye, Elena Barnaeva, Lesley A. Mathews Griner, Noel Southall, Xin Hu, Amy Q. Wang, Xin Xu, Andrés E. Dulcey, Juan Marugán, Marc Ferrer, Ravit Arav‐Boger

    Publicado em 2016
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  8. 8
    Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia

    Immune dysfunction signatures predict outcomes and define checkpoint blockade–unresponsive microenvironments in acute myeloid leukemia por Sergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, Stephen Reeder, Tung On Yau, Rupkatha Mukhopadhyay, Benjamin Dickins, Heidi Altmann, Michael Krämer, Hanna A. Knaus, Bruce R. Blazar, Vedran Radojčić, Joshua F. Zeidner, Andrea Arruda, Bofei Wang, Hussein A. Abbas, Mark D. Minden, Sarah K. Tasian, Martin Bornhäuser, Ivana Gojo, Leo Luznik

    Publicado em 2022
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:
  9. 9
    Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

    Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia por Joshua F. Zeidner, Benjamin G. Vincent, Anastasia Ivanova, Dominic T. Moore, Karen P. McKinnon, Alec Wilkinson, Rupkatha Mukhopadhyay, Francesco Mazziotta, Hanna A. Knaus, Matthew C. Foster, Catherine C. Coombs, Katarzyna Jamieson, Hendrik Van Deventer, Jonathan Webster, Gabrielle T. Prince, Amy E. DeZern, B. Douglas Smith, Mark J. Levis, Nathan D. Montgomery, Leo Luznik, Jonathan S. Serody, Ivana Gojo

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Salvar na lista
    Na minha lista:

Ferramentas de busca: